1. Search Result
Search Result
Results for "

nicotinic acid derivatives

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-126477
    NNK
    2 Publications Verification

    Endogenous Metabolite Cancer
    NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser 70 and c-Myc at Thr 58 and Ser 62 through activation of both ERK1/2 and PKCα . NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure .
    NNK
  • HY-101701

    Megrin

    Drug Derivative Cardiovascular Disease
    Hepronicate, a nicotinic acid derivative, is a peripheral vasodilator with blood lipid lowering action. Hepronicate works by improving peripheral circulatory disturbances .
    Hepronicate
  • HY-B0283
    Acipimox
    2 Publications Verification

    K-9321

    Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox
  • HY-N3359

    D-Lupanine

    nAChR Neurological Disease
    Lupanine (D-Lupanine) is a natural ketonic derivative of Sparteine (HY-W008350) with a ganglioplegic activity. Lupanine shows binding affinity for nicotinic receptor with a Ki value of 500 nM .
    Lupanine
  • HY-W015806

    Endogenous Metabolite Metabolic Disease
    3-Pyridineacetic acid is an orally active nicotinic acid analog. 3-Pyridineacetic acid enhances cholesterol oxidation in rat liver mitochondria. 3-Pyridineacetic acid inhibits Triton-induced hypercholesterolemia in rats. 3-Pyridineacetic acid can be used in research related to hypercholesterolemia .
    3-Pyridineacetic acid
  • HY-133027

    Tetradecyl nicotinate

    Biochemical Assay Reagents Cancer
    Myristyl nicotinate (Tetradecyl nicotinate) is an ester proagent and a lipophilic derivative of Nicotinic acid. Myristyl nicotinate is being developed for delivery of Nicotinic acid into the skin for prevention of actinic keratosis and its progression to skin cancer. Myristyl nicotinate shows to stimulate epidermal differentiation in photodamaged skin, increasing skin NAD content and strengthening the skin barrier .
    Myristyl nicotinate
  • HY-W012617

    nicotinic acid hydrazide

    Drug Intermediate Infection
    Nicotinohydrazide (Nicotinic acid hydrazide) is a precursor used for synthesizing hydrazone derivatives with antibacterial and antifungal activities. Nicotinohydrazide can be used in studies of bacterial and fungal infections .
    Nicotinohydrazide
  • HY-W273281

    MOFs Others
    6,6′-Dithiodinicotinic acid is a sulfur-containing organic compound belonging to nicotinic acid derivatives, which can be used as a specific sulfhydryl blocker .
    6,6′-Dithiodinicotinic acid
  • HY-N3359B

    D-Lupanine hydrochloride

    nAChR Neurological Disease
    Lupanine (D-Lupanine) hydrochloride is a natural ketonic derivative of Sparteine (HY-W008350) with a ganglioplegic activity. Lupanine hydrochloride shows binding affinity for nicotinic receptor with a Ki value of 500 nM .
    Lupanine hydrochloride
  • HY-B0283A

    K-9321 sodium

    Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox sodium
  • HY-178935

    Amylases Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    α-Amylase-IN-14, a derivative of Nicotinic (HY-B0143), is an α-amylase inhibitor and has good interactions with α-amylase protein (-5.55 kcal/mol). α-Amylase-IN-14 is a dual anti-inflammatory and anti-hyperglycemic agent. α-Amylase-IN-14 exhibits good results against DPPH and ABTS radicals. α-Amylase-IN-14 can be used for the study of diabetes .
    α-Amylase-IN-14
  • HY-133027R

    Tetradecyl nicotinate (Standard)

    Biochemical Assay Reagents Reference Standards Cancer
    Myristyl nicotinate (Standard) is the analytical standard of Myristyl nicotinate. This product is intended for research and analytical applications. Myristyl nicotinate (Tetradecyl nicotinate) is an ester proagent and a lipophilic derivative of Nicotinic acid. Myristyl nicotinate is being developed for delivery of Nicotinic acid into the skin for prevention of actinic keratosis and its progression to skin cancer. Myristyl nicotinate shows to stimulate epidermal differentiation in photodamaged skin, increasing skin NAD content and strengthening the skin barrier .
    Myristyl nicotinate (Standard)
  • HY-106559

    GCGR Cardiovascular Disease
    Sorbinicate, a derivative of nicotinic acid, exerts a favourable influence on blood rheology and platelet function .
    Sorbinicate
  • HY-B0283R

    K-9321 (Standard)

    Carbonic Anhydrase Reference Standards Metabolic Disease
    Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox (Standard)
  • HY-N3359A

    D-Lupanine perchlorate

    nAChR Neurological Disease
    Lupanine (D-Lupanine) perchlorate is a natural ketonic derivative of Sparteine (HY-W008350)with a ganglioplegic activity. Lupanine perchlorate shows binding affinity for nicotinic receptor with a Ki value of 500 nM .
    Lupanine perchlorate
  • HY-161508

    Cholinesterase (ChE) Neurological Disease
    AChE/BChE-IN-19 (Compound 12) is a nicotinic hydrazide derivative. AChE/BChE-IN-19 is a inhibitor of AChE (IC50 = 21.45 nM) and BChE (IC50 =18.42 nM). AChE/BChE-IN-19 can be used in Alzheimer's disease research .
    AChE/BChE-IN-19
  • HY-19013

    Drug Derivative Cardiovascular Disease
    L44-0 is a nicotinic acid derivative. L44-0 reduces atherosclerotic lesions and decreases vascular norepinephrine levels in the renal arteries, femoral arteries, and veins in a New Zealand white rabbit model of atherosclerosis. L44-0 can be used in research on cardiovascular and cerebrovascular diseases such as atherosclerosis .
    L 44-0
  • HY-126477R

    Reference Standards Endogenous Metabolite Cancer
    NNK (Standard) is the analytical standard of NNK. This product is intended for research and analytical applications. NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser70 and c-Myc at Thr58 and Ser62 through activation of both ERK1/2 and PKCα . NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure .
    NNK (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: